OSE Immunotherapeutics : Positive phase II results for lusvertikimab in ulcerative colitis
>Potential first-in-class anti-IL7R therapy - OSE announced positive results for the induction portion (10 weeks’ treatment) for phase II (CoTikis) evaluating lusvertikimab (anti-IL7R) in 136 patients with moderate to severe ulcerative colitis (UC), in treatment failure, lacking response or intolerant to one of more prior treatments (corticosteroids, STI or biologics). The trial thus achieved its primary endpoint demonstrating clinically and statistically significant ...Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.